South Africa Anticoagulant Market By Drug Class (Vitamin K Antagonist (Warfarin), Non-VKA Oral Anticoagulants (NOACS), Heparin & LMWH, Thrombin Inhibitors (Dabigatran)), Therapeutic Areas (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack, Stroke, Unstable Angina, Hip Or Knee Replacement Surgery, Others), Route Of Administration (Oral, Parenteral), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
South Africa Anticoagulant Market Analysis and Size
The anticoagulant market comprises features such as strategic initiatives by market players that will impact the launching of new drugs by the manufacturers into the market which enhance its demand as well as technological advancements have enhanced the demand for anticoagulant drugs. Currently, various research studies are taking place which are expected to create a competitive advantage for manufacturers to develop new innovative and advanced anticoagulant drugs which are expected to provide various other opportunities in the anticoagulant market. However, increasing government restrictions are expected to restraint the market growth in the forecast period.
Data Bridge Market Research analyzes that the South Africa anticoagulant market which was USD 30,773.20 million in 2023, is likely to reach USD 57,337.50 million by 2031, and is expected to undergo a CAGR of 5.1% during the forecast period. “Vitamin K Antagonist (Warfarin)” dominates the drug class segment of the market and is growing due to the increasing prevalence of blood related disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2017-2022)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Vitamin K Antagonist (Warfarin), Non-VKA Oral Anticoagulants (NOACS), Heparin & LMWH, Thrombin Inhibitors (Dabigatran)), Therapeutic Areas (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack, Stroke, Unstable Angina, Hip Or Knee Replacement Surgery, Others), Route Of Administration (Oral, Parenteral), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Market Players Covered
|
Sanofi (France), Fresenius Kabi AG (A subsidiary of Fresenius SE & Co KGaA) (Germany), Aspen Holdings (South Africa), Cipla Inc. (India), Bayer AG (Germany), Pfizer Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Adcock Ingram (South Africa)
|
|
Market Opportunities
|
|
Market Definition
An anticoagulant is a substance that prevents blood from clotting. These medications are commonly used to treat or prevent blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and after certain surgeries. Anticoagulants work by interfering with the body's natural blood-clotting process, thereby reducing the risk of abnormal clot formation. Examples of anticoagulants include heparin, warfarin, and direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, and apixaban.
South Africa Anticoagulant Market Dynamics
Drivers
- Rising prevalence of cardiovascular diseases
South Africa, like many other countries, is witnessing an increase in cardiovascular diseases, which often necessitate anticoagulant therapy. As the population ages and lifestyle factors impact health, the demand for anticoagulants rises.
- Increasing awareness and healthcare access
Increased awareness about the risks associated with thrombosis and embolism has led to greater diagnosis and treatment. Better access to healthcare services and medications also contributes to the growth of the anticoagulant market.
Opportunities
- Rising Advancements in Healthcare Infrastructure
As the healthcare infrastructure improves, there is an increase in access to healthcare services, including the diagnosis and treatment of cardiovascular diseases, which often require anticoagulant therapy. The advancement in healthcare infrastructure also leads to the availability of advanced diagnostic tools and technologies, this early detection can lead to timely intervention and better outcomes for patients. The rising advancement in healthcare infrastructure presents a significant opportunity for the market.
- Increasing adoption of novel anticoagulants
The shift from traditional anticoagulants (like warfarin) to newer, more convenient options like direct oral anticoagulants (DOACs) is influencing the market. These newer drugs offer advantages such as fewer interactions, less need for monitoring, and potentially lower risk of bleeding complications.
Restraints
- Regulatory Approvals and Compliance
Regulatory processes and approvals for newer anticoagulants may influence their availability in the market. Delays in approvals or stringent regulatory requirements can affect the timely introduction of innovative treatments.
- Cost and Affordability
Affordability remains a significant challenge for many patients. Anticoagulants, especially the newer options, can be expensive, making them inaccessible to a large portion of the population. This is particularly relevant considering the prevalence of cardiovascular diseases requiring long-term anticoagulation therapy.
Challenges
- Preference for Traditional Therapies
Despite the benefits of newer anticoagulants, there might be a preference for traditional options like warfarin due to familiarity, cost, or perceived effectiveness. This preference can slow the adoption of newer, potentially more efficient treatments.
This anticoagulant market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anticoagulant market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2019, Bristol-Myers Squibb- Pfizer Alliance received safety and efficacy data related to Eliquis for the treatment of venous thromboembolism in patients suffering from active cancer. This efficacy data helped the company to provide physicians and patients with growing opportunity to treat venous thromboembolism that lead to more product sales
South Africa Anticoagulant Market Scope
Anticoagulant market is segmented on the basis of drug class, therapeutic areas, route of administration, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Drug Class
- Vitamin K Antagonist (Warfarin)
- Non-VKa Oral Anticoagulants (NOACs)
- Heparin & LMWH
- Thrombin Inhibitors (Dabigatran)
Therapeutic Areas
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation
- Heart Attack
- Stroke
- Unstable Angina
- Hip or Knee Replacement Surgery
- Others
Route Of Administration
- Oral
- Parenteral
Type
- In-House
- Outsource
End User
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Healthcare Infrastructure growth Installed base and New Technology Penetration
Anticoagulant market also provides you with detailed market analysis for South Africa country growth in anticoagulant industry with anticoagulant sales, impact of advancement in the anticoagulant and changes in regulatory scenarios with their support for the anticoagulant market. The data is available for historic period 2010-2021.
Competitive Landscape and South Africa Anticoagulant Market Share Analysis
Anticoagulant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to anticoagulant market.
Some of the major players operating in the anticoagulant market are:
- Sanofi (France)
- Fresenius Kabi AG (A subsidiary of Fresenius SE & Co KGaA) (Germany)
- Aspen Holdings (South Africa)
- Cipla Inc. (India)
- Bayer AG (Germany)
- Pfizer Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Adcock Ingram (South Africa)
SKU-